Prescription: More Profits, Less Regulation
The recent recall of a generic cholesterol medication by Aurobindo Pharma, cited for 'failed dissolution specifications,' is presented as a minor hiccup. Yet, this isn't an isolated incident, but a symptom of a broader issue where drug manufacturers, especially those producing generics, face minimal scrutiny until a failure is too obvious to ignore. For instance, the FDA's enforcement capabilities
have been consistently underfunded, while pharmaceutical lobbying, totaling over $376 million in 2023 alone ( OpenSecrets.org ), ensures that regulations remain as porous as some recalled pills. One might wonder if a similar 'failed dissolution' of ethical standards is at play when we see politicians, many of whom receive substantial campaign contributions from the pharmaceutical sector,
consistently vote against measures for stricter drug oversight. How many undetected 'failures' are consumers ingesting daily while the industry churns out products that barely meet specifications, often manufactured overseas with even less oversight? It appears the only consistent 'dissolution' is that of public trust, skillfully managed by PR departments and compliant media. (The Hill, link
provided ).